These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 27528374)

  • 61. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
    Mikhail N
    Postgrad Med; 2012 Jul; 124(4):138-44. PubMed ID: 22913902
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.
    Waldrop G; Zhong J; Peters M; Rajagopalan S
    J Am Coll Cardiol; 2016 Mar; 67(12):1488-1496. PubMed ID: 27012410
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis.
    Wu Y; Lu Y; Yang S; Zhang Q
    J Int Med Res; 2021 Dec; 49(12):3000605211066306. PubMed ID: 34939442
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
    Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer.
    Hidayat K; Zhou YY; Du HZ; Qin LQ; Shi BM; Li ZN
    Pharmacoepidemiol Drug Saf; 2023 Feb; 32(2):107-125. PubMed ID: 36224724
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Carbone LJ; Angus PW; Yeomans ND
    J Gastroenterol Hepatol; 2016 Jan; 31(1):23-31. PubMed ID: 26111358
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Incretin-mimetic therapies and pancreatic disease: a review of observational data.
    Suarez EA; Koro CE; Christian JB; Spector AD; Araujo AB; Abraham S
    Curr Med Res Opin; 2014 Dec; 30(12):2471-81. PubMed ID: 25180611
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2017 May; 127():224-237. PubMed ID: 28402902
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Ding S; Du YP; Lin N; Su YY; Yang F; Kong LC; Ge H; Pu J; He B
    Int J Cardiol; 2016 Nov; 222():957-962. PubMed ID: 27526367
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
    Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
    Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials.
    Singh AK; Gangopadhyay KK; Singh R
    Expert Rev Clin Pharmacol; 2020 Apr; 13(4):461-468. PubMed ID: 32129106
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis.
    Oikonomaki D; Dounousi E; Duni A; Roumeliotis S; Liakopoulos V
    Diabetes Res Clin Pract; 2021 Feb; 172():108604. PubMed ID: 33338553
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
    Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
    Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
    MacIsaac RJ; Thomas MC
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):321-323. PubMed ID: 29321176
    [No Abstract]   [Full Text] [Related]  

  • 76. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
    van Baar MJB; van Raalte DH
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):103-111. PubMed ID: 31714285
    [TBL] [Abstract][Full Text] [Related]  

  • 77. DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
    Abe M; Okada K
    Contrib Nephrol; 2015; 185():98-115. PubMed ID: 26023019
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
    Abe M; Okada K; Soma M
    Curr Drug Metab; 2011 Jan; 12(1):57-69. PubMed ID: 21303332
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes.
    Triplitt C; McGill JB; Porte D; Conner CS
    J Manag Care Pharm; 2007 Dec; 13(9 Suppl C):S2-16; quiz S17. PubMed ID: 18062735
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.
    Wang T; Wang F; Gou Z; Tang H; Li C; Shi L; Zhai S
    Diabetes Obes Metab; 2015 Jan; 17(1):32-41. PubMed ID: 25200423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.